Effects of active bufadienolide compounds on human cancer cells and CD4+CD25+Foxp3+ regulatory T cells in mitogen-activated human peripheral blood mononuclear cells

  • Authors:
    • Bo Yuan
    • Jing He
    • Keishi Kisoh
    • Hideki Hayashi
    • Sachiko Tanaka
    • Nan Si
    • Hai-Yu Zhao
    • Toshihiko Hirano
    • Baolin Bian
    • Norio Takagi
  • View Affiliations

  • Published online on: July 18, 2016     https://doi.org/10.3892/or.2016.4946
  • Pages: 1377-1384
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The growth inhibitory effects of bufadienolide compounds were investigated in two intractable cancer cells, a human glioblastoma cell line U-87 and a pancreatic cancer cell line SW1990. Among four bufadienolide compounds, a dose-dependent cytotoxicity was observed in these cancer cells after treatment with gamabufotalin and arenobufagin. The IC50 values of the two compounds were 3-5 times higher in normal peripheral blood mononuclear cells (PBMCs) than these values for both cancer cell lines. However, similar phenomena were not observed for two other bufadienolide compounds, telocinobufagin and bufalin. These results thus suggest that gamabufotalin and arenobufagin possess selective cytotoxic activity against tumor cells rather than normal cells. Moreover, a clear dose-dependent lactate dehydrogenase (LDH) release, a well-known hallmark of necrosis, was observed in both cancer cells treated with gamabufotalin, suggesting that gamabufotalin-mediated cell death is predominantly associated with a necrosis-like phenotype. Of most importance, treatment with as little as 8 ng/ml of gamabufotalin, even an almost non-toxic concentration to PBMCs, efficiently downregulated the percentages of CD4+CD25+Foxp3+ regulator T (Treg) cells in mitogen-activated PBMCs. Given that Treg cells play a critical role in tumor immunotolerance by suppressing antitumor immunity, these results suggest that gamabufotalin may serve as a promising candidate, as an adjuvant therapeutic agent by manipulating Treg cells to enhance the efficacy of conventional anticancer drugs and lessen their side-effects. These findings provide insights into the clinical application of gamabufotalin for cancer patients with glioblastoma/pancreatic cancer based on its cytocidal effect against tumor cells as well as its depletion of Treg cells.
View Figures
View References

Related Articles

Journal Cover

September-2016
Volume 36 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yuan B, He J, Kisoh K, Hayashi H, Tanaka S, Si N, Zhao H, Hirano T, Bian B, Takagi N, Takagi N, et al: Effects of active bufadienolide compounds on human cancer cells and CD4+CD25+Foxp3+ regulatory T cells in mitogen-activated human peripheral blood mononuclear cells. Oncol Rep 36: 1377-1384, 2016.
APA
Yuan, B., He, J., Kisoh, K., Hayashi, H., Tanaka, S., Si, N. ... Takagi, N. (2016). Effects of active bufadienolide compounds on human cancer cells and CD4+CD25+Foxp3+ regulatory T cells in mitogen-activated human peripheral blood mononuclear cells. Oncology Reports, 36, 1377-1384. https://doi.org/10.3892/or.2016.4946
MLA
Yuan, B., He, J., Kisoh, K., Hayashi, H., Tanaka, S., Si, N., Zhao, H., Hirano, T., Bian, B., Takagi, N."Effects of active bufadienolide compounds on human cancer cells and CD4+CD25+Foxp3+ regulatory T cells in mitogen-activated human peripheral blood mononuclear cells". Oncology Reports 36.3 (2016): 1377-1384.
Chicago
Yuan, B., He, J., Kisoh, K., Hayashi, H., Tanaka, S., Si, N., Zhao, H., Hirano, T., Bian, B., Takagi, N."Effects of active bufadienolide compounds on human cancer cells and CD4+CD25+Foxp3+ regulatory T cells in mitogen-activated human peripheral blood mononuclear cells". Oncology Reports 36, no. 3 (2016): 1377-1384. https://doi.org/10.3892/or.2016.4946